Perphenazine description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Perphenazine

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

WARNING

Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Perphenazine is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).

PERPHENAZINE DESCRIPTION



Perphenazine

ACTIONS


CLINICAL PHARMACOLOGY

Pharmacokinetics


Parameter Perphenazine 7-Hydroxyperphenazine

INDICATIONS & USAGE



PERPHENAZINE CONTRAINDICATIONS



WARNINGS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Perphenazine is not approved for the treatment of patients with dementia-related psychosis (see BOXED WARNING).





Information for PatientsandADVERSE REACTIONS.)

Neuroleptic Malignant Syndrome (NMS)










Usage in Pregnancy







PRECAUTIONS

Leukopenia, Neutropenia and Agranulocytosis



















Drug Interactions



Information for Patients



Geriatric Use

WARNINGS). Elderly patients taking psychotropic drugs may be at increased risk for falling and consequent hip fractures. Elderly patients should be started on lower doses and observed closely.

PERPHENAZINE ADVERSE REACTIONS



CNS Effects
Not all of the following adverse reactions have been reported with this specific drug; however, pharmacological similarities among various phenothiazine derivatives require that each be considered. With the piperazine group (of which perphenazine is an example), the extrapyramidal symptoms are more common, and others (e.g., sedative effects, jaundice, and blood dyscrasias) are less frequently seen.












WARNINGS).




Autonomic Effects



Allergic Effects
urticaria, erythema, eczema, exfoliative dermatitis, pruritus, photosensitivity, asthma, fever, anaphylactoid reactions, laryngeal edema, and angioneurotic edema; contact dermatitis in nursing personnel administering the drug; and in extremely rare instances, individual idiosyncrasy or hypersensitivity to phenothiazines has resulted in cerebral edema, circulatory collapse, and death.


Endocrine Effects


Cardiovascular Effects



Hematological Effects


Other Effects


DOSAGE & ADMINISTRATION





Moderately disturbed nonhospitalized patients with schizophrenia


Hospitalized patients with schizophrenia


Severe nausea and vomiting in adults


Elderly Patients

OVERDOSAGE



Manifestations


Treatment

CONTRAINDICATIONS.)



HOW SUPPLIED


2 mg: debossed GG 18 on one side and plain on the reverse side, supplied as:



4 mg:debossed GG 107 on one side and plain on the reverse side, supplied as:




8 mg:debossed GG 108 on one side and plain on the reverse side, supplied as:




16 mg:debossed GG 109 on one side and plain on the reverse side, supplied as:



STORAGE AND HANDLING


PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION














Perphenazine

Perphenazine

PERPHENAZINE TABLET, FILM COATED

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:52125-102(NDC:0781-1047)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
PERPHENAZINE PERPHENAZINE 4 mg

Inactive Ingredients

Ingredient Name Strength
cellulose, microcrystalline
hydroxypropyl cellulose
HYPROMELLOSES
HYPROMELLOSE 2910 (3 MPA.S)
lactose monohydrate
MAGNESIUM STEARATE
polyethylene glycol
polysorbate 80
STARCH, CORN
titanium dioxide

Product Characteristics

Color Size Imprint Code Shape
white 7 mm GG107 ROUND

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:52125-102-20 100 in 1 VIAL

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA089684 2012-09-26


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.